Prof. Seamas Donnelly

1,154 views

Published on

Clinical Reality, Ethical Issues and Patient Needs in AAL and Connected Health in Respiratory Medicine

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,154
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Prof. Seamas Donnelly

  1. 1. Professor S é amas C. Donnelly St Vincent’s University Hospital, Elm Park, Dublin September 2 nd . 2010 Clinical Validation of Novel Remote Technologies
  2. 2. Translational Medicine <ul><li>Translational Medicine </li></ul>
  3. 3. Translational Medicine <ul><li>Translational Medicine </li></ul>
  4. 4. Translational Medicine <ul><li>Translational Medicine </li></ul><ul><li>Medical Director Clinical Research Centre (CRC) </li></ul>
  5. 5. Translational Medicine <ul><li>Translational Medicine </li></ul><ul><li>Medical Director Clinical Research Centre (CRC) </li></ul><ul><li>Inflammatory Cell Biology Research Group </li></ul>
  6. 6. Translational Medicine Grant Funding The Wellcome Trust European Union Science Foundation Ireland (SFI) <ul><li>Translational Medicine </li></ul><ul><li>Medical Director Clinical Research Centre (CRC) </li></ul><ul><li>Inflammatory Cell Biology Research Group </li></ul>
  7. 7. Translational Medicine Grant Funding The Wellcome Trust European Union Science Foundation Ireland (SFI) Publications Nature Medicine Journal Clinical Investigation Lancet Genes & Immunity Proceedings National Academy Sciences Journal of Experimental Medicine Immunity <ul><li>Translational Medicine </li></ul><ul><li>Medical Director Clinical Research Centre (CRC) </li></ul><ul><li>Inflammatory Cell Biology Research Group </li></ul>
  8. 8. Translational Medicine “ Bench to Bedside”
  9. 9. Translational Medicine “ Bench to Bedside” <ul><li>Regulation of the inflammatory response </li></ul><ul><li>Candidate Gene Susceptibility </li></ul><ul><li>Defining Biomarkers for Disease </li></ul><ul><li>Remote Monitoring & Integrated </li></ul><ul><li>Clinical Networks </li></ul>
  10. 10. Translational Medicine “ Bench to Bedside” <ul><li>Regulation of the inflammatory response </li></ul><ul><li>Candidate Gene Susceptibility </li></ul><ul><li>Defining Biomarkers for Disease </li></ul><ul><li>Remote Monitoring & Integrated </li></ul><ul><li>Clinical Networks </li></ul>
  11. 11. Translational Medicine
  12. 12. Translational Medicine Healthcare – The Problem
  13. 13. Translational Medicine Healthcare – The Problem An Ageing Population
  14. 14. Translational Medicine Healthcare – The Problem An Ageing Population 2010 65 + – 41 million 85 + – 5 million 2050 65 + - 87 Million 85 + - 21 Million
  15. 15. Translational Medicine Healthcare – The Problem An Ageing Population Healthcare Costs
  16. 16. Translational Medicine Healthcare – The Problem An Ageing Population Healthcare Costs $5,152 (2001) $12,019 (2015)
  17. 17. Translational Medicine Healthcare Costs & Chronic Disease <ul><li>Chronic Obstructive Pulmonary Disease (COPD) </li></ul><ul><li>Asthma </li></ul><ul><li>Congestive Cardiac Failure (CCF) </li></ul><ul><li>Diabetes Mellitus </li></ul><ul><li>Coronary Heart Disease </li></ul>> 80% 0f Healthcare Costs
  18. 18. Translational Medicine Healthcare Costs & Chronic Disease <ul><li>Chronic Obstructive Pulmonary Disease (COPD) </li></ul><ul><li>Asthma </li></ul><ul><li>Congestive Cardiac Failure (CCF) </li></ul><ul><li>Diabetes Mellitus </li></ul><ul><li>Coronary Heart Disease </li></ul>> 80% 0f Healthcare Costs
  19. 19. Translational Medicine Chronic Obstructive Pulmonary Disease (COPD) 8% of 65 + US Population
  20. 20. Translational Medicine Chronic Obstructive Pulmonary Disease (COPD) 8% of 65 + US Population 5 th . Commonest cause of Death 2 nd . commonest A/E Admission
  21. 21. Translational Medicine Chronic Obstructive Pulmonary Disease (COPD) 8% of 65 + US Population 5 th . Commonest cause of Death 2 nd . commonest A/E Admission Average LOS: 7.5 days
  22. 22. Translational Medicine Chronic Obstructive Pulmonary Disease (COPD) 8% of 65 + US Population 5 th . Commonest cause of Death 2 nd . commonest A/E Admission Average LOS: 7.5 days 30% chance of readmission Average LOS: 11 days
  23. 23. Translational Medicine Chronic Obstructive Pulmonary Disease (COPD) 8% of 65 + US Population 5 th . Commonest cause of Death 2 nd . commonest A/E Admission Average LOS: 7.5 days 30% chance of readmission Average LOS: 11 days Direct Costs: $24.9 Billion Indirect Costs: $ 8.8 Billion $33.7 Billion
  24. 24. Translational Medicine Chronic Obstructive Pulmonary Disease (COPD
  25. 25. Translational Medicine Chronic Obstructive Pulmonary Disease (COPD Diagnosis Clinical History Pulmonary Functions Studies
  26. 26. Translational Medicine Normal COPD
  27. 27. Translational Medicine Chronic Obstructive Pulmonary Disease (COPD Treatment
  28. 28. Translational Medicine Chronic Obstructive Pulmonary Disease (COPD Treatment <ul><li>Clinical Unmet Need </li></ul><ul><li>Compliance </li></ul><ul><li>Markers of Effectiveness </li></ul><ul><li>Acute Hospital/ </li></ul><ul><li>Community Costs </li></ul>
  29. 29. Translational Medicine “ Integrated Clinical Networks”
  30. 30. Translational Medicine “ Integrated Clinical Networks” University College Dublin St. Vincent’s University Hospital 300,000 Population
  31. 31. Translational Medicine St. Vincent’s University Hospital “ Integrated Clinical Networks” COPD (Dr Butler, Dr McDonnell, Prof. Donnelly) CCF (Dr. Ledwidge, Prof. McDonald)
  32. 32. Translational Medicine St. Vincent’s University Hospital “ Integrated Clinical Networks” COPD (Dr Butler, Dr McDonnell, Prof. Donnelly) CCF (Dr. Ledwidge, Prof. McDonald) Asthma Pulmonary Fibrosis
  33. 33. Translational Medicine “ Integrated Clinical Networks” Clinical Research Centre (CRC) St Vincent’s University Hospital Monitor in Real-Time Patient well-being
  34. 34. Translational Medicine “ Integrated Clinical Networks” Academic/Industrial Collaborations Analog Devices Shimmer Technologies BiancaMed CLARITY TRIL
  35. 35. Translational Medicine Professor Seamas Donnelly St. Vincent’s University Hospital & University College Dublin E-mail: [email_address]

×